Heart disease breakthrough as ‘gene silencer’ drug shows promise - The Independent
- Heart disease breakthrough as ‘gene silencer’ drug shows promise The Independent
- Full study data back Alnylam heart drug’s benefit, but leave doctors with tough choices BioPharma Dive
- Alnylam's Amvuttra turns in 'grand slam' showing in ATTR-CM, but leaves a window open for rivals FiercePharma
- HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM TCTMD
- Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress Yahoo Finance